# Medisix Therapeutics Pte

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/medisix-therapeutics-pte

- Industry: Biotechnology
- Headquarters: Singapore, Singapore
- Website: www.medisixtx.com
- Total disclosed funding: $20M
- Latest round: Series A (Feb 7, 2018)
- Investors on record: 3

## About

Medisix Therapeutics Pte Ltd. is a biotechnology company focused on developing innovative T-cell therapies to address complex and rare T-cell malignancies, improving treatment options for patients in need.Founded in 2016, Medisix Therapeutics is based in Singapore and specializes in biotechnology. The company has engaged in 2 significant deals and raised a total of USD 20.36 mn in funding, with the latest round completed on September 17, 2019. Andrew Bruce is the CEO, leading the company towards advancing T-cell therapy. No major pivots in business strategy have been reported.Medisix Therapeutics develops cutting-edge T-cell therapies, prominently featuring its PEBL (Protein Expression BLocker) technology that enhances CAR T-cell therapies. This technology aims to improve T-cell function for treating conditions such as T-cell acute lymphoblastic leukemia (T-ALL), catering to healthcare providers, research institutions, and pharmaceutical companies primarily in Singapore.In 2023, Medisix Therapeutics reported zero revenue and an EBITDA loss of USD 28,763,317. Revenue generation is driven through partnerships and collaborations with healthcare institutions focused on T-cell therapies, structured around research agreements and clinical trial partnerships utilizing the PEBL platform.Medisix Therapeutics plans to leverage its funding of USD 20.36 mn from September 2019 to further develop its PEBL technology and expand into new markets. Upcoming product launches are expected to include enhancements to current therapies, with specific geographic expansions being targeted in Asia and the United States by 2025. The company aims to establish a solid pipeline for future clinical trials and commercialization.

## Funding rounds

- Series A, Feb 7, 2018, $20M — Temasek Holdings, OUP (Osage University Partners), Lightstone Ventures

## Investors

- Temasek Holdings — Series A
- OUP (Osage University Partners) (https://capitalatlas.ai/funds/oup-osage-university-partners) — Series A
- Lightstone Ventures (https://capitalatlas.ai/funds/lightstone-ventures) — Series A